Cancer

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.

Study finds genetic factor undermines H. pylori treatment

Helicobacter pylori, a stomach-dwelling bacterium, is a strong risk factor for gastric cancer, peptic ulcers and other debilitating gastrointestinal disorders. Yet efforts to eradicate it using a combination of antibiotics and proton pump inhibitors (PPIs), which suppress gastric acid production, often fail.

Prediction models for breast cancer

Vanderbilt researchers developed new prognostic models for breast cancer outcomes and found that adding postdiagnostic weight change as a factor improves the prediction.

Mood and cognition after chemotherapy

Validation of cognitive complaints appears to improve mood in patients with persistent chemotherapy-cognitive impairment, Vanderbilt researchers report.

Susan G. Komen funds VICC breast cancer initiatives

Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

1 19 20 21 22 23 69